COMPANY
Artery Therapeutics, Inc.
Funding and NIH signals
- NIH award NIH awarded $2.27M (SBIR Phase II 1R44AG099463-01, new, notice Sep 17, 2026); 2 NIH awards totaling $4.91M in the last 12 months. NIH RePORTER 1R44AG099463-01 (Sep 17, 2026)
Evidence (2 events)
- Sep 17, 2026 · NIH RePORTER 1R44AG099463-01
Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1R44AG099463-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2267403; Administering IC: National Institute on Aging; Project title: Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK; Organization type: Domestic For-Profits - Mar 3, 2026 · NIH RePORTER 1UG3AG098023-01
Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1UG3AG098023-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-03-03; FY total cost (award amount): 2644490; Administering IC: National Institute on Aging; Project title: CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker Effects; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44AG099463-01
Timeline
- Grant Government grant — SBIR: $2.27M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
- Grant Government grant — NIH UG3: $2.64M (annual award, as published), announced Mar 3, 2026. Agency: NIH/NIA. Source: government award database. source ↗
- Grant Government grant — SBIR: $2.45M (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIA. Source: government award database. source ↗
- Trial start Early phase 1: Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers source ↗
Funding
- Government grant — SBIR: $2.27M (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIA. Source: government award database. source ↗
- Government grant — NIH UG3: $2.64M (annual award, as published), announced Mar 3, 2026. Agency: NIH/NIA. Source: government award database. source ↗
- Government grant — SBIR: $2.45M (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05965414 | Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers | Early phase 1 | Completed | Oct 23, 2023 | Jul 31, 2024 (actual) |
NIH awards 4
- NIH award 4R44AG076299-02 FY2023: $2,482,205 awarded for that fiscal year; activity R44 (SBIR); PI JOHANSSON, JAN; recipient as written: ARTERY THERAPEUTICS, INC., SAN RAMON, CA. A randomized double-blind placebo con source ↗
- NIH award 1R44AG076299-01 FY2021: $499,197 awarded for that fiscal year; activity R44 (SBIR); PI JOHANSSON, JAN; recipient as written: ARTERY THERAPEUTICS, INC., SAN RAMON, CA. A randomized double-blind placebo contr source ↗
- NIH award 4R44AG060826-02 FY2020: $2,375,985 awarded for that fiscal year; activity R44 (SBIR); PI JOHANSSON, JAN; recipient as written: ARTERY THERAPEUTICS, INC., SAN RAMON, CA. CS6253 development for the treatment source ↗
- NIH award 1R44AG060826-01A1 FY2019: $479,682 awarded for that fiscal year; activity R44 (SBIR); PI JOHANSSON, JAN; recipient as written: ARTERY THERAPEUTICS, INC., SAN RAMON, CA. CS6253 development for the treatment source ↗